Immunocore Holdings plc (IMCR)
Automate Your Wheel Strategy on IMCR
With Tiblio's Option Bot, you can configure your own wheel strategy including IMCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMCR
- Rev/Share 6.6601
- Book/Share 7.5565
- PB 4.8435
- Debt/Equity 0.1122
- CurrentRatio 6.3597
- ROIC -0.0463
- MktCap 1836756689.0
- FreeCF/Share 0.5199
- PFCF 70.5306
- PE -84.7592
- Debt/Assets 0.0413
- DivYield 0
- ROE -0.0586
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IMCR | Deutsche Bank | -- | Buy | -- | $65 | May 27, 2025 |
| Downgrade | IMCR | Morgan Stanley | Overweight | Equal Weight | $74 | $35 | Dec. 13, 2024 |
| Downgrade | IMCR | Guggenheim | Buy | Neutral | -- | -- | Oct. 7, 2024 |
News
Is it a Good Idea to Invest in Immunocore Stock Right Now?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.
Read More
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
New Strong Buy Stocks for May 8th
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
BTSG, NWFL, MNRO, UBSI and IMCR have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2025.
Read More
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Immunocore (IMCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Insiders Make Huge Purchases of These 4 Biotech Stocks
Published: March 26, 2025 by: 24/7 Wall Street
Sentiment: Neutral
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Read More
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Read More
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025
Read More
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025.
Read More
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.
Read More
About Immunocore Holdings plc (IMCR)
- IPO Date 2021-02-05
- Website https://www.immunocore.com
- Industry Biotechnology
- CEO Dr. Bahija Jallal Ph.D.
- Employees 493